Association of ST2 polymorphisms with atopy, asthma, and leukemia
To the Editor:
The phenome-wide association study (PheWAS) is a new, validated, reverse genetics approach that associates genetic variants of interest with phenotypes by linking a database of deidentified genotyping to a broad range of electronic medical record-derived clinical phenotypes. 1 Although the more common genome-wide association study (GWAS) is useful in identifying genetic polymorphisms that may relate to one particular disease phenotype, PheWAS's ability to evaluate these polymorphisms against an entire database of clinical phenotypes greatly expands the scope of genomic association research. Using a PheWAS, one is able to examine polymorphisms detected in the context of a disease to not only confirm this established association with greater certainty, but one may uncover links to entirely new phenotypes that had not been previously considered or investigated at the genetic level. 1 IL-33 is one of the most consistently associated gene candidates for asthma identified by GWASs in diverse ethnic groups.
2 IL-33 is a central mediator of both innate-and adaptive immunity-regulated allergic inflammation in the lung. 3, 4 The primary binding partner of IL-33, ST2, is a member of the IL-1 receptor family that is expressed on a number of immune cells, including ILC2, CD4
1 T H 2 cells, mast cells, and eosinophils. 5 GWASs investigating polymorphisms related to asthma have identified a number of single nucleotide polymorphisms (SNPs) in the ST2 receptor gene. 6, 7 We sought to investigate these polymorphisms to assess the role of ST2 signaling in other, non-asthma-related allergic diseases. In addition, we hoped to identify new diseases in which genetic links to the ST2 receptor had not been reported. We performed a PheWAS on 15 ST2 genetic variants implicated in asthma to assess their associations with other allergic and nonallergic diseases. The Exome BeadChip that we used to perform the PheWAS genotyped 38 variants in IL1R1. We only included variants with a minor allele threshold (mean allele frequency [MAF]) of greater than 1%; this filtering is necessary to support a PheWAS analysis using a logistic regression. The PheWAS used a cohort of 36,400 adult (age > 18 years) subjects who had genotyping on Illumina HumanExome BeadChip version 1.1 and available electronic health record (EHR) data from the Vanderbilt BioVU DNA biobank that was ascertained previously for 5 different criteria: (1) eligibility as case or control in 1 of 31 pharmacogenetic studies, (2) available longitudinal data with primary care visits, (3) presence in the cancer registry, (4) old age with longitudinal data, and (5) presence of rare diseases or conditions ascertained via billing codes. Of the 15 SNPs, 6 had MAFs greater than 1% in the total cohort population, rendering them sufficiently powered for further analysis.
1 All these 6 SNPs are in the ST2 gene (human chromosome 2q11.2). 6 The PheWAS yields results as a list of phenotype International Classification of Diseases, Ninth Revision (ICD-9) codes that best associated with each particular SNP.
Our study revealed that the minor allele of ST2 SNP rs1041973 associated with allergic conjunctivitis (odds ratio [OR] 5 1.27), an allergic disease that had not been linked genetically in the context of IL-33/ST2 signaling. We further demonstrate that the minor allele of rs1041973 exhibits an inverse association with eosinophilia, as indicated by an OR of less than 1 (0.686; Table I ). In addition, the PheWAS confirmed the previously reported inverse relationship of 5 ST2 SNPs with asthma (rs10192036: OR 5 0.876; rs1041973: OR 5 0.505; rs4988956: OR 5 0.876; rs10192157: OR 5 0.876; rs10206753: OR 5 0.876), and it confirmed the formerly identified association of rs1420101 (OR 5 1.20) with asthma. 6, 7 We calculated the pair-wise linkage disequilibrium for each of the 6 variants tested and found that the minor alleles of rs10192036, rs10206753, rs4988956, and rs10192157 are in perfect linkage (r 2 5 1). For this reason, the associations of these 4 SNPs are reported under only rs4988956. These genomic investigations with study populations entirely separate from our own provide ORs in similar directions for all 6 SNPs investigated in this study, confirming the previously described association of each. 6, 7 This further supports the validity of our method by demonstrating that genetic and phenotypic data from Vanderbilt University Medical Center patients is representative of national and international populations. 6 Finally, the PheWAS uncovered a novel association of 2 SNPs in the ST2 gene with various forms of leukemia (Table II) . The minor allele of the SNP rs1420101 associated with leukemia and acute myeloid leukemia, whereas the minor allele of rs1041973 associated with leukemia, acute myeloid leukemia, and acute lymphoid leukemia.
The results of this study inform our understanding of the ST2 pathway as it relates to other, nonasthmatic forms of allergic disease. We are also the first to identify rs1041973 as a genetic variant that associates inversely with eosinophilia. In an analysis of peripheral blood eosinophilia for eosinophilia-associated rs1041973 cases and controls, there was a significant increase in the maximum-recorded percentage of peripheral blood eosinophilis in cases (13.5%) compared with controls (3.4%; P 5 3.15 3 102
165 ; see Table E1 in this article's Online Repository at www.jacionline.org). Because SNPs examined in this study were originally identified in a GWAS as relevant to asthma, the associations that we report here with asthma serve as another indicator of the reliability of PheWAS as an analytical technique, and of the validity of the asthma-ST2 connection. We repeated our study in an independent cohort of more than 500,000 subjects, the UK Biobank. 8 We verified our previously identified allergic and asthmatic phenotype associations with ST2 polymorphisms in the UK Biobank using self-reported phenotype codes (see Table E2 in this article's Online Repository at www.jacionline.org). Finally, our findings establish the first genetic link between the ST2 gene and leukemia. We were unable to confirm our associations to lymphoma and leukemia due to an insufficient number of these disease cases in the UK Biobank cohort. However, the association between ST2 polymorphisms and multiple forms of leukemia can be supported by a handful of in vivo and in vitro studies that have reported IL-33 and ST2 to be potential mediators of leukemic cell proliferation. 9 These findings identify novel genetic risk factors for leukemia, and provide further support for the investigation of this signaling pathway in leukocyte tumorigenesis. The significance of these results is further demonstrated by the fact that 5 of the 6 SNPs discussed in this study have MAFs of more than 37%. These polymorphisms are present in a substantial portion of the US population, and their continued investigation will no doubt yield widespread benefit.
Although PheWASs such as this one offer inexpensive and efficient insight into the association of disease with specific genetic variants, the model itself has certain intrinsic limitations. First, a selection bias exists, as the genotyping information available for the study comes from patients who have had blood drawn for laboratory testing. In addition, most subjects who provided blood were admitted to the emergency department or hospital, further compromising the true randomness of the test samples. Furthermore, the study reports uncorrected P values as well as P values adjusted with the false-discovery rate correction. A Bonferroni correction may be used to reduce the likelihood of type I statistical error. However, this study was performed as an exploratory analysis. Therefore, we excluded the use of multiple testing corrections to reduce our type II error rate. In situations such as this study in which the number of tests is large, multiple testing corrections can be overly conservative, possibly contributing to missed or overlooked results. A limitation of our approach is that it depends on the prior identification of SNPs in other studies or the sufficiently high prevalence of SNPs in our cohort of study. For this reason, the number of SNPs available for PheWAS is limited, and important genetic associations in the ST2 gene likely remain undiscovered. In addition, inherent limitations exist in the study's dependence on disease phenotype diagnosis with ICD codes. ICD-9 billing codes are often a poor and unspecific diagnostic tool, and variation exists in the application of these codes by physicians and the ability of the algorithms to assign code designations to more narrative, textual diagnoses. This is particularly true in the case of asthma in which the diagnoses are difficult to confirm in the EHR, because not every patient will have lung function or methacholine challenge tests performed.
In conclusion, these data demonstrate the utility of PheWAS by identifying links between polymorphisms in the ST2 gene and multiple forms of leukemia. Furthermore, they implicate specific ST2 SNPs in allergic diseases not previously tied genetically to [1] [2] [3] Patients with HIES manifest with elevated serum IgE level, atopy, recurrent pulmonary and skin bacterial infections, chronic mucocutaneous candidiasis (CMC), locally invasive pulmonary aspergillosis, and connective tissue abnormalities. [1] [2] [3] However, STAT3 mutations resulting in haploinsufficiency and their associated phenotypes have not been well characterized to date. Herein, we describe a patient with a de novo STAT3 splice-site mutation resulting in STAT3 haploinsufficiency who presented with elevated IgE level, allergic rhinitis, eosinophilic esophagitis, and fatal invasive aspergillosis.
Our patient was a 37-year-old man with a 1-year history of eosinophilic esophagitis and allergic rhinitis, which was treated with occasional topical steroids. The patient developed subacute symptoms of headache and sinus pain that did not respond to several courses of antibacterial antibiotics, and progressed to develop facial numbness, diplopia, and visual loss over the course of 4 weeks. He was found to have a locally invasive sino-orbital infection with cavernous sinus involvement (Fig 1, A-D) . Sinus tissue biopsy showed chronic inflammation and invasive fungal acute-angle branching hyphae (Fig 1, E and F) . Sinus cultures grew Aspergillus fumisynnematus as identified by morphology and the sequences of beta-tubulin and DNA replication licensing factor Mcm7. Minimum inhibitory concentrations (in mg/mL) for the isolate were as follows: micafungin, 0.015 or less; amphotericin, 2; posaconazole, 0.25; voriconazole, 0.25; and terbinafine, 0.06. The patient underwent multiple surgical debridements with removal of infected necrotic tissue, including right orbital exenteration, and was treated over time with various antifungal drug combinations (amphotericin B, micafungin, voriconazole, posaconazole, terbinafine), adjunct immunotherapy (IFN-g, GM-CSF), and hyperbaric oxygen. Despite these efforts, the infection progressed into the right middle cranial fossa and meninges (Fig 1, A-D) and the patient died 1 year after his sino-orbital symptoms began. Of note, the patient's infection did not involve the lungs or other distal anatomical sites, nor did he have any underlying lung disease. He had no family history of atopy or unusual infections. The patient had normal blood lymphocyte, monocyte, and neutrophil counts. At presentation, his eosinophil count was transiently mildly elevated (range, 100-1090/mL). His serum IgE level was elevated at 1003 IU/mL, whereas all other immunoglobulin levels were within normal range. A dihydrorhodamine test was normal. Other unremarkable laboratory tests included antineutrophil cytoplasmic antibodies, antinuclear antibody, complement CH50, and HIV antibody. Pneumococcal antibody titers were positive in 3 out of 14 serotypes tested. We ruled out an acquired immunodeficiency state caused by autoantibodies against IFN-g, IL-17A, GM-CSF, or IL-12 (data not shown).
Before his death, the patient was evaluated at the National Institutes of Health Clinical Center and he was enrolled on an institutional review board-approved research protocol. Informed consent was obtained from the patient and his family members. Whole-exome sequencing was performed using DNA isolated from whole blood from the patient and his unaffected sister and nonconsanguineous parents (Fig 2, A) . No mutations were found in STAT1, CARD9, other genes encoding members of the C-type lectin receptor signaling pathway, or the 5 nicotinamide adenine dinucleotide phosphate oxidase subunits, all of which are critical for systemic antifungal host defense. 4 A novel, de novo STAT3 splice-site mutation was found before exon 13 (c.1140-3C>G) on the maternal haplotype, which was confirmed by Sanger sequencing using DNA extracted from whole blood and from formalin-fixed sinus tissue biopsy (data not shown). Sequencing of this locus in the patient's son did not reveal this mutation (Fig 2, A) . This mutation was not observed in the 1000 Genomes, Exome Sequencing Project, or gnomAD databases (February 2018 access), which include exome data from more than
METHODS

PheWAS methodology
We used phecodes to define phenotypic features from the EHR. Phecodes are defined by hierarchical groupings of ICD-9 codes and were developed to enable research based on readily available and computable billing code data for PheWASs. They have been validated in a broad range of genetic association studies, and have been shown to replicate 66% of tested known associations for a diverse set of phenotypes with an area under the receiveroperator characteristic curve of 0.83. The version of phecodes (V1.1) used in this article can be downloaded at http://phewascatalog.org. We defined cases as individuals with 2 or more phecodes on unique dates and controls and individuals who do not have a phecode within the control range. For this study, phecode associations with SNPs yielding uncorrected P values lower than .05 were considered significant. Further technical details regarding the development and application of PheWAS can be found in our previous publications.
E1,E2
The sequencing was performed using the Illumina human exome genotyping array clustering and quality control protocol developed by the Vanderbilt Epidemiology Center in cooperation with Vanderbilt Technologies for Advanced Genomics Analysis and Research Design. The detailed protocol for this sequencing technique has been previously reported.
E3
Eosinophilia phenotype validation
In this study, eosinophilia refers to peripheral blood eosinophilia as diagnosed and documented by the subject's physician. We performed an analysis of peripheral blood eosinophilia for eosinophilia-associated rs1041973 cases and controls. There was a significant increase in the maximum-recorded percentage of peripheral blood eosinophils in cases (13.5%) compared with controls (3.4%; P 5 3.15 3 10
2165
; Table E1 ).
Replication of results in independent cohorts
To validate the associations that we present in this letter, we repeated our study in 3 independent cohorts: the UK Biobank, the Vanderbilt BioVU MEGA Project, and the Marshfield Clinic Personalized Medicine Research Project. Of these 3, the Vanderbilt BioVU MEGA Project (7,212 subjects) and the Marshfield Clinic Personalized Medicine Research Project (20,000) cohorts were underpowered to detect statistically significant differences. However, we were successful in replicating our allergic and asthmatic phenotype associations with ST2 SNPs in the UK Biobank (500,000 subjects) using self-reporting phenotype codes (Table E2 ). We were unable to confirm our associations to leukemia and lymphoma due to an insufficient number of cases in the cohort. 
